preto-perola-shutterstock-com-1

Preto Perola / Shutterstock.com

12 November 2015Big PharmaDuncan Ribbons and Maeve Lynch

CRISPR: the shifting sands of patentability

CRISPR/Cas9 (clustered regularly interspaced short palindromic repeat/CRISPR-associated protein 9) technology is a revolutionary method of modifying genomic sequences. Although genomic modification has been possible for many years, CRISPR technology is cheaper, easier and more accurate than the modification tools preceding it.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

G 2/21: how to support inventive steps in patentability

7 April 2022 A new referral to the European Patent Office’s enlarged board of appeal will determine whether post-filed data can be used to support inventive steps in patentability, as Sarah Gibbs of Appleyard Lees reports.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More on this story

article

G 2/21: how to support inventive steps in patentability

7 April 2022 A new referral to the European Patent Office’s enlarged board of appeal will determine whether post-filed data can be used to support inventive steps in patentability, as Sarah Gibbs of Appleyard Lees reports.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More on this story

article

G 2/21: how to support inventive steps in patentability

7 April 2022 A new referral to the European Patent Office’s enlarged board of appeal will determine whether post-filed data can be used to support inventive steps in patentability, as Sarah Gibbs of Appleyard Lees reports.

USPTO ignites CRISPR/Cas9 patent battle

13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.

More features

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

GSK triumphs in EPO appeal, revoking Pfizer patent

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

Teva fights for re-listing of inhaler patents at US appeals court

CRISPR patents revoked following Nobel Prize winners’ withdrawal

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst